NasdaqGS:KRYSBiotechs
Is A Single-Patient KB801 Outcome Quietly Reframing Krystal Biotech's Clinical Narrative (KRYS)?
Krystal Biotech recently filed a response with the U.S. Patent and Trademark Office for its KB801 gene therapy, disclosing past data from a discontinued neurotrophic keratitis study in which one patient experienced complete closure of a persistent corneal epithelial defect without reported serious safety issues.
The company emphasized that this previously undisclosed, single-patient outcome is being shared now only because it will appear in the public patent record and should not be...